| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 13694 | 2012 |
| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 13694 | 2012 |
| Safety and activity of anti–PD-L1 antibody in patients with advanced cancer JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ... New England Journal of Medicine 366 (26), 2455-2465, 2012 | 8738 | 2012 |
| Nivolumab plus ipilimumab in advanced melanoma JD Wolchok, H Kluger, MK Callahan, MA Postow, NA Rizvi, AM Lesokhin, ... New England Journal of Medicine 369 (2), 122-133, 2013 | 4970 | 2013 |
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ... Journal of clinical oncology 32 (10), 1020, 2014 | 2657 | 2014 |
| Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ... Journal of clinical oncology 33 (18), 2004, 2015 | 1281 | 2015 |
| Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab DF McDermott, CG Drake, M Sznol, TK Choueiri, JD Powderly, DC Smith, ... Journal of clinical oncology 33 (18), 2013, 2015 | 458 | 2015 |
| Combination immunotherapy: a road map PA Ott, FS Hodi, HL Kaufman, JM Wigginton, JD Wolchok Journal for immunotherapy of cancer 5, 1-15, 2017 | 368 | 2017 |
| The C3 (1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma JE Green, MA Shibata, K Yoshidome, M Liu, C Jorcyk, MR Anver, ... Oncogene 19 (8), 1020-1027, 2000 | 302 | 2000 |
| Immunotherapy of cancer by IL-12-based cytokine combinations JM Weiss, JJ Subleski, JM Wigginton, RH Wiltrout Expert opinion on biological therapy 7 (11), 1705-1721, 2007 | 283 | 2007 |
| Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy S Gnjatic, V Bronte, LR Brunet, MO Butler, ML Disis, J Galon, ... Journal for immunotherapy of cancer 5, 1-18, 2017 | 228 | 2017 |
| IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells R Salcedo, JK Stauffer, E Lincoln, TC Back, JA Hixon, C Hahn, ... The Journal of Immunology 173 (12), 7170-7182, 2004 | 215 | 2004 |
| Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary R Gorlick, P Anderson, I Andrulis, C Arndt, GP Beardsley, M Bernstein, ... Clinical Cancer Research 9 (15), 5442-5453, 2003 | 206 | 2003 |
| Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma JM Wigginton, KL Komschlies, TC Back, JL Franco, MJ Brunda, ... JNCI: Journal of the National Cancer Institute 88 (1), 38-43, 1996 | 197 | 1996 |
| IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy JM Wigginton, E Gruys, L Geiselhart, J Subleski, KL Komschlies, JW Park, ... The Journal of clinical investigation 108 (1), 51-62, 2001 | 190 | 2001 |
| Defining the critical hurdles in cancer immunotherapy BA Fox, DJ Schendel, LH Butterfield, S Aamdal, JP Allison, PA Ascierto, ... Journal of translational medicine 9, 1-15, 2011 | 187 | 2011 |
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): A single-arm, phase 1b–2 trial DVT Catenacci, YK Kang, H Park, HE Uronis, KW Lee, MCH Ng, ... The lancet oncology 21 (8), 1066-1076, 2020 | 160 | 2020 |
| Anti‐tumour synergy of cytotoxic chemotherapy and anti‐CD40 plus CpG‐ODN immunotherapy through repolarization of tumour‐associated macrophages IN Buhtoiarov, PM Sondel, JM Wigginton, TN Buhtoiarova, EM Yanke, ... Immunology 132 (2), 226-239, 2011 | 153 | 2011 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling JP Cogswell, SM Goldberg, AK Gupta, M Jure-Kunkel, XT Wang, ... US Patent 9,856,320, 2018 | 141 | 2018 |
| Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma … R Salcedo, JA Hixon, JK Stauffer, R Jalah, AD Brooks, T Khan, RM Dai, ... The Journal of Immunology 182 (7), 4328-4338, 2009 | 125 | 2009 |
